Rohit Loomba

An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice

Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis.

Social Determinants of Health in Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause/Cause-Specific Mortality.

Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy.

Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA).

AI-driven synthetic data generation for accelerating hepatology research: A study of the United Network for Organ Sharing (UNOS) database.

Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency–Associated Liver Disease

Global Longitudinal Assessment of <scp>MASLD</scp> Using Magnetic Resonance Elastography ( <scp>GOLDMINE</scp> ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in <scp>MASLD</scp> Clinical Outcomes

Cardiovascular Risk Assessment Tools are Insufficient for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Clinical Utility of a 50% and 30% Decline in Magnetic Resonance Imaging-Proton Density Fat Fraction in Predicting Fibrosis Improvement in Metabolic Dysfunction-associated Steatohepatitis

Editorial: Gene Silencing Therapy for a New Era of Pancreatitis Prevention. Authors' Reply.

Reply: Placebo drift, dose heterogeneity, and the winner's curse-Re-evaluating the hierarchy of MASH therapeutics.

Reply: Considerations on the diagnostic accuracy and applicability of MASHResInd in MASH resolution.

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD, MetALD and ALD.

Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution.

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis.

Association of Components of Metabolic Syndrome and the Progression of Nonalcoholic Fatty Liver Disease.

Clinical Use of Noninvasive Testing for Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease

The MetALD-ALD Prediction Index: A Phosphatidylethanol-Driven Biomarker Panel for Identifying Individuals With Steatotic Liver Disease and Excessive Alcohol Use

Editorial: Gene Silencing Therapy for a New Era of Pancreatitis Prevention. Authors' Reply

Metabolic dysfunction-associated steatotic liver disease in adults

Metabolic dysfunction-associated steatotic liver disease in adults.

Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis

Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials

AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials

The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021

Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (<scp>MASLD</scp>) and Metabolic Dysfunction‐Associated Steatohepatitis (<scp>MASH</scp>): From the Growing Prevalence to Payors' Perspective

Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of <scp>MetALD</scp> Versus <scp>MASLD</scp>: A Prospective Study